Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors

Öz:

Objective: Cardiovascular disease (CVD) is more prevalentin almost all patients with chronic inflammatory musculoskeletal diseases than in their healthy counterparts. The aim of thisstudy was to assess the presence of subclinical atherosclerosisin patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthritis (RA) and healthy controls.Methods: A total of 30 patients with PsA, 30 patients with RA,and 30 healthy controls were enrolled in this parallel groupstudy. Demographic, clinical, and laboratory data of the groupswere recorded. The Disease Activity Score-28 tool was usedfor joint assessment. The erythrocyte sedimentation rate andC-reactive protein level were measured as acute phase reactants. Flow-mediated dilatation (FMD) and carotid intima mediathickness (CIMT) were also measured in all participants.Results: The median duration of disease in patients withPsA was 60 months (range: 8–216 months). A total of 22 of30 (73.3%) PsA patients had a diagnosis of psoriasis and13 (48.1%) had active disease. The study groups were similar with regard to age, gender, and body mass index data. Inall, 23 (76.7%) of the PsA patients and 5 (16.7%) of the RApatients were using an anti-tumor necrosis factor alpha therapy (p<0.001). The FMD percentage was significantly smallerin both the PsA and the RA patients than in the healthy controls (p<0.001). The median CIMT was greater in the RA patients compared with the PsA patients and the healthy controls(p=0.008). There was no significant difference in FMD or CIMTbetween patients with and without an active joint lesion.Conclusion: Endothelial functions were impaired in PsA, as inRA, in the absence of conventional risk factors or overt CVD.This finding may show a potential association between PsA,atherosclerosis, and CVD.

Anahtar Kelime:

Klinik olarak aşikar kardiyovasküler hastalığı ya da geleneksel ateroskleroz risk faktörü bulunmayan psöriatik artritli hastalarda subklinik aterosklerozun değerlendirilmesi

Öz:

Amaç: Kardiyovasküler hastalıklar kronik enflamatuvar kasiskelet hastalığı olan hastaların hemen hepsinde sağlıklı akranlarına göre daha sıktır. Bu çalışmada psöriatik artritli (PsA) hastalarda subklinik ateroskleroz varlığı hem romatoid artrit (RA) hem de sağlıklı kontrol bireyleri ile karşılaştırılarak değerlendirilmiştir. Yöntemler: Paralel grup çalışmamıza PsA bulunan 30 hasta, RA bulunan 30 hasta ve 30 sağlıklı kontrol bireyi alındı. Katılımcıların tüm demografik, klinik ve laboratuvar verileri kaydedildi. Eklem aktivitesi hastalık aktivite skoru (DAS)-28 ile değerlendirildi. Eritrosit sedimentasyon hısı (ESH) ve C-reaktif protein (CRP) düzeyleri akut faz reaktanı olarak ölçüldü. Tüm katılımcılarda akım aracılı dilatasyon (AAD) ve karotis intima mediya kalınlığı (KİMK) ölçüldü. Bulgular: Psöriatik artritli hastalardaki ortanca hastalık süresi 60 (dağılım, 8–216) aydı. 22/30 (%73.3) PsA’lı hastalarda psöriasis tanısı daha önce konmuştu ve bunların 13/30’unda (%48.1) hastalık aktifti. Çalışma grupları yaş, cinsiyet ve vücut kitle indeksi açısından benzerdi. Yirmi üç (%76.7) PsA’lı hasta ve RA’lı beş (%16.7) hastaya anti-tümör nekrozis faktör (TNF)- alfa tedavisi uygulanıyordu (p<0.001). AAD yüzdesi hem PsA’lı hem de RA’lı hastalarda sağlıklı kontrollere göre belirgin olarak düşüktü (p<0.001). Ortanca KİMK ise RA’lı hastalarda PsA’lı hastalar ve sağlıklı gruba göre belirgin yüksekti (p=0.008). Aktif eklem lezyonu olan ve olmayan hastalarda hem AAD yüzdesi hem de ortanca KİMK benzerdi. Sonuç: Geleneksel risk faktörleri ya da aşikar kardiyovasküler hastalık olmaksızın PsA’da RA’ya benzer şekilde endotel fonksiyonları bozulmuştur. Bu durum PsA ile ateroskleroz ve KVH arasındaki potansiyel ilişkiyi gösterebilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73. [CrossRef]
2. Di Minno MN, Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med 2015;47:346–53. [CrossRef]
3. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012;38:497–505. [CrossRef]
4. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131–5. [CrossRef]
5. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868–72. [CrossRef]
6. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211–6. [CrossRef]
7. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63.
8. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al; Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233–46. [CrossRef]
9. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011;10:773–8. [CrossRef]
10. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322–31. [CrossRef]
11. Yilmazer B, Sahin T, Unlu BÖ, Kir HM, Cefle A. Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 2015;35:1385– 92. [CrossRef]
12. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7– 17. [CrossRef]
13. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67. [CrossRef]
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81. [CrossRef]
15. Yorgun H, Tokgözoğlu L, Canpolat U, Gürses KM, Bozdağ G, Yapıcı Z, et al. The cardiovascular effects of premature ovarian failure. Int J Cardiol 2013;168:506–10. [CrossRef]
16. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011;18:775–89. [CrossRef]
17. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167–72.
18. Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide populationbased study. Ann Rheum Dis 2010;69:1165–8. [CrossRef]
19. Castañeda S, Martín-Martínez MA, González-Juanatey C, Llorca J, García-Yébenes MJ, Pérez-Vicente S, et al; CARMA Project Collaborative Group. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. Semin Arthritis Rheum 2015;44:618–26. [CrossRef]
20. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326–32. [CrossRef]
21. Martín-Martínez MA, González-Juanatey C, Castañeda S, Llorca J, Ferraz-Amaro I, Fernández-Gutiérrez B, et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 2014;44:1–8. [CrossRef]
22. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 2008;47:718–23. [CrossRef]
23. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203–9. [CrossRef]
24. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074–80. [CrossRef]
25. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, AmigoDiaz E, Testa A, Garcia-Porrua C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287–93. [CrossRef]
26. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008;35:877–82.
27. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic dis eases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69–75. [CrossRef]
28. Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, et al. Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 2015;17:75.
29. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–26. [CrossRef]
30. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–95. [CrossRef]
31. Shoenfeld Y, Sherer Y, Harats D. Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001;22:293–5. [CrossRef]
32. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999;100:951–7. [CrossRef]
33. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399–406.
34. Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012;2012:714321. [CrossRef]
35. Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, et al. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data [Article in Italian]. Reumatismo 2009;61:298–305.
36. Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011;38:1661–4. [CrossRef]
37. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705–12. [CrossRef]
38. Jókai H, Szakonyi J, Kontár O, Marschalkó M, Szalai K, Kárpáti S, et al. Impact of effective tumor necrosis factoralfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 2013;69:523–9. [CrossRef]
39. Jahangiri A. High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 2010;17:156– 60. [CrossRef]

APA	Apras Bilgen S, KALYONCU U, ERDEN A, CANPOLAT U, Oral H, KARADAĞ Ö, AYTEMIR K, KİRAZ S, AKDOĞAN A, ERTENLİ İ (2018). Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. , 358 - 365. 10.5543/tkda.2018.36169
Chicago	Apras Bilgen Sule,KALYONCU Umut,ERDEN Abdülsamet,CANPOLAT Uğur,Oral Hakan,KARADAĞ ÖMER,AYTEMIR KUDRET,KİRAZ Sedat,AKDOĞAN Ali,ERTENLİ İhsan Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. (2018): 358 - 365. 10.5543/tkda.2018.36169
MLA	Apras Bilgen Sule,KALYONCU Umut,ERDEN Abdülsamet,CANPOLAT Uğur,Oral Hakan,KARADAĞ ÖMER,AYTEMIR KUDRET,KİRAZ Sedat,AKDOĞAN Ali,ERTENLİ İhsan Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. , 2018, ss.358 - 365. 10.5543/tkda.2018.36169
AMA	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. . 2018; 358 - 365. 10.5543/tkda.2018.36169
Vancouver	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. . 2018; 358 - 365. 10.5543/tkda.2018.36169
IEEE	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ "Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors." , ss.358 - 365, 2018. 10.5543/tkda.2018.36169
ISNAD	Apras Bilgen, Sule vd. "Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors". (2018), 358-365. https://doi.org/10.5543/tkda.2018.36169

APA	Apras Bilgen S, KALYONCU U, ERDEN A, CANPOLAT U, Oral H, KARADAĞ Ö, AYTEMIR K, KİRAZ S, AKDOĞAN A, ERTENLİ İ (2018). Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi, 46(5), 358 - 365. 10.5543/tkda.2018.36169
Chicago	Apras Bilgen Sule,KALYONCU Umut,ERDEN Abdülsamet,CANPOLAT Uğur,Oral Hakan,KARADAĞ ÖMER,AYTEMIR KUDRET,KİRAZ Sedat,AKDOĞAN Ali,ERTENLİ İhsan Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi 46, no.5 (2018): 358 - 365. 10.5543/tkda.2018.36169
MLA	Apras Bilgen Sule,KALYONCU Umut,ERDEN Abdülsamet,CANPOLAT Uğur,Oral Hakan,KARADAĞ ÖMER,AYTEMIR KUDRET,KİRAZ Sedat,AKDOĞAN Ali,ERTENLİ İhsan Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi, vol.46, no.5, 2018, ss.358 - 365. 10.5543/tkda.2018.36169
AMA	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi. 2018; 46(5): 358 - 365. 10.5543/tkda.2018.36169
Vancouver	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors. Türk Kardiyoloji Derneği Arşivi. 2018; 46(5): 358 - 365. 10.5543/tkda.2018.36169
IEEE	Apras Bilgen S,KALYONCU U,ERDEN A,CANPOLAT U,Oral H,KARADAĞ Ö,AYTEMIR K,KİRAZ S,AKDOĞAN A,ERTENLİ İ "Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors." Türk Kardiyoloji Derneği Arşivi, 46, ss.358 - 365, 2018. 10.5543/tkda.2018.36169
ISNAD	Apras Bilgen, Sule vd. "Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors". Türk Kardiyoloji Derneği Arşivi 46/5 (2018), 358-365. https://doi.org/10.5543/tkda.2018.36169